DE69932832D1 - Antagonisten auf rezeptorgrundlage und verfahren zur deren herstellung und verwendung - Google Patents

Antagonisten auf rezeptorgrundlage und verfahren zur deren herstellung und verwendung

Info

Publication number
DE69932832D1
DE69932832D1 DE69932832T DE69932832T DE69932832D1 DE 69932832 D1 DE69932832 D1 DE 69932832D1 DE 69932832 T DE69932832 T DE 69932832T DE 69932832 T DE69932832 T DE 69932832T DE 69932832 D1 DE69932832 D1 DE 69932832D1
Authority
DE
Germany
Prior art keywords
production
receptor based
based antagonists
fusion polypeptides
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69932832T
Other languages
English (en)
Other versions
DE69932832T2 (de
Inventor
Neil Stahl
D Yancopoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69932832D1 publication Critical patent/DE69932832D1/de
Publication of DE69932832T2 publication Critical patent/DE69932832T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
DE69932832T 1998-09-25 1999-09-22 Antagonisten auf rezeptorgrundlage und verfahren zu deren herstellung und verwendung Expired - Lifetime DE69932832T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10185898P 1998-09-25 1998-09-25
US101858P 1998-09-25
US09/313,942 US6472179B2 (en) 1998-09-25 1999-05-19 Receptor based antagonists and methods of making and using
US313942 1999-05-19
PCT/US1999/022045 WO2000018932A2 (en) 1998-09-25 1999-09-22 Receptor based antagonists and methods of making and using

Publications (2)

Publication Number Publication Date
DE69932832D1 true DE69932832D1 (de) 2006-09-28
DE69932832T2 DE69932832T2 (de) 2007-02-08

Family

ID=26798712

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69922269T Expired - Lifetime DE69922269T2 (de) 1998-09-25 1999-09-22 IL-1 Rezeptor Fusionsproteine verwendet als Antagoniste und Verfahren zu deren Verwendung und Herstellung
DE69932832T Expired - Lifetime DE69932832T2 (de) 1998-09-25 1999-09-22 Antagonisten auf rezeptorgrundlage und verfahren zu deren herstellung und verwendung
DE201012000023 Active DE122010000023I2 (de) 1998-09-25 2010-04-13 IL-1 Rezeptor Fusionsproteine verwendet als Antagoniste und Verfahren zu deren Verwendung und Herstellung.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69922269T Expired - Lifetime DE69922269T2 (de) 1998-09-25 1999-09-22 IL-1 Rezeptor Fusionsproteine verwendet als Antagoniste und Verfahren zu deren Verwendung und Herstellung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE201012000023 Active DE122010000023I2 (de) 1998-09-25 2010-04-13 IL-1 Rezeptor Fusionsproteine verwendet als Antagoniste und Verfahren zu deren Verwendung und Herstellung.

Country Status (19)

Country Link
US (2) US6472179B2 (de)
EP (3) EP1229047B1 (de)
JP (1) JP3902728B2 (de)
CN (1) CN100345970C (de)
AT (2) ATE336583T1 (de)
AU (1) AU758970C (de)
BE (1) BE2010C021I2 (de)
CA (1) CA2345109C (de)
DE (3) DE69922269T2 (de)
DK (1) DK1229047T3 (de)
ES (2) ES2267300T3 (de)
FR (1) FR10C0025I2 (de)
HK (2) HK1035377A1 (de)
IL (2) IL142103A0 (de)
NO (2) NO329976B1 (de)
NZ (1) NZ510720A (de)
PL (1) PL201246B1 (de)
PT (1) PT1229047E (de)
WO (1) WO2000018932A2 (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
CA2318482C (en) 1998-01-23 2010-04-13 Immunex Corporation Il-18 receptors
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US7083949B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
ES2382891T3 (es) 2000-05-26 2012-06-14 Immunex Corporation Uso de anticuerpos IL-4R y sus composiciones
CA2447632C (en) 2000-06-16 2011-08-02 Asterion Limited Fusion protein agonist comprising a growth hormone binding portion and an external domain of a growth hormone receptor
CA2418950A1 (en) * 2000-08-08 2002-02-14 Zymogenetics, Inc. Soluble zcytor 11 cytokine receptors
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050112616A1 (en) * 2001-12-10 2005-05-26 William Lee Functionalized materials and libraries thereof
US7795213B2 (en) * 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US6846520B2 (en) * 2002-01-17 2005-01-25 Canon Kabushiki Kaisha Epoxy resin composition, surface treatment method, liquid-jet recording head and liquid-jet recording apparatus
US6811780B2 (en) 2002-05-01 2004-11-02 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat HIV infection and AIDS
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
KR101329843B1 (ko) * 2002-11-15 2013-11-14 젠맵 에이/에스 Ｃｄ25에 대한 인간 모노클로날 항체
US6919012B1 (en) 2003-03-25 2005-07-19 Olimex Group, Inc. Method of making a composite article comprising a ceramic coating
ES2327409T3 (es) 2003-03-26 2009-10-29 Apogenix Gmbh Proteinas de fusion fc mejoradas.
US20040224893A1 (en) * 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
WO2004098596A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and il-1 trap
US20050118683A1 (en) * 2003-06-11 2005-06-02 Wood Clive R. Method for producing a polypeptide
DK1648940T3 (en) * 2003-07-28 2016-08-15 Genentech Inc Reduction of leaching of protein A during protein A affinity chromatography
AU2004270774A1 (en) * 2003-09-05 2005-03-17 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
BRPI0416603A (pt) 2003-11-07 2007-01-30 Immunex Corp anticorpo que se liga ao receptor interleucina-4 (il-4) humano
EP1723173B1 (de) * 2004-02-27 2008-05-14 Regeneron Pharmaceuticals, Inc. Il-4/il-13-spezifische polypetide und deren therapeutische verwendung
JP5022216B2 (ja) 2004-06-04 2012-09-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法
CA2891010C (en) 2004-07-23 2022-09-20 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
WO2006023665A2 (en) * 2004-08-17 2006-03-02 Regeneron Pharmaceuticals, Inc. Il-1 antagonist formulations
PT1630232E (pt) * 2004-08-27 2008-10-02 Conaris Res Inst Ag Sequências de nucleótidos optimizadas que codificam sgp130
US7786261B2 (en) * 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
WO2006031689A2 (en) * 2004-09-13 2006-03-23 Genzyme Corporation Multimeric constructs
MX2007004374A (es) * 2004-10-12 2008-01-29 Amprotein Corp Proteina quimerica.
CN101198625A (zh) 2004-10-22 2008-06-11 津莫吉尼蒂克斯公司 抗il-22ra抗体和结合伴侣及其在炎症中的使用方法
EP1848738A1 (de) * 2005-01-25 2007-10-31 Apollo Life Sciences Limited Parameterausgewählte gm-csf, il-3, il-4, il-5 und chimären davon für therapeutische und diagnostische zwecke
EP1861116B1 (de) 2005-03-25 2015-09-16 Regeneron Pharmaceuticals, Inc. Vegf-antagonistenformulierungen
US7732167B2 (en) * 2005-06-17 2010-06-08 Regeneron Pharmaceuticals, Inc. Interferon-α/β binding fusion proteins and therapeutic uses thereof
US7608430B2 (en) * 2005-07-08 2009-10-27 Regeneron Pharmaceuticals, Inc. Interferon-γ antagonists and therapeutic uses thereof
PL2298815T3 (pl) 2005-07-25 2015-08-31 Emergent Product Dev Seattle Zmniejszenie ilości komórek B przy użyciu cząsteczek wiążących specyficznych dla CD20 i CD37
US7666622B2 (en) * 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US7889347B2 (en) 2005-11-21 2011-02-15 Plexera Llc Surface plasmon resonance spectrometer with an actuator driven angle scanning mechanism
ME00380B (me) * 2005-11-23 2011-10-10 Acceleron Pharma Inc Amtagonisti aktivin-actriia i primjene za stimulaciju rasta kosti
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US7463358B2 (en) 2005-12-06 2008-12-09 Lumera Corporation Highly stable surface plasmon resonance plates, microarrays, and methods
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
EP2041178A2 (de) 2006-06-12 2009-04-01 Trubion Pharmaceuticals, Inc. Multivalente einzelkettenbindungsproteine mit effektorfunktion
SI2944306T1 (sl) 2006-06-16 2021-04-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
DE602006016765D1 (de) 2006-06-30 2010-10-21 Conaris Res Inst Ag Verbesserte sgp 130Fc Dimere
EP2412383A1 (de) 2006-07-28 2012-02-01 Children's Memorial Hospital Verfahren zur Hemmung von Tumorzellenaggressivität anhand der Mikroumgebung menschlicher embryonaler Stammzellen
US8106004B2 (en) * 2006-07-28 2012-01-31 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
US7632490B2 (en) * 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
PL2124997T3 (pl) * 2006-10-20 2013-01-31 Regeneron Pharma Zastosowanie antagonistów IL-1 do leczenia dny moczanowej i dny rzekomej
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
JP5272735B2 (ja) * 2007-01-30 2013-08-28 国立大学法人 新潟大学 生物学的製剤
MX2009008222A (es) 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TWI432449B (zh) 2007-02-02 2014-04-01 Acceleron Pharma Inc 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TW201808334A (zh) 2007-02-09 2018-03-16 艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
EP2578684B1 (de) 2007-03-19 2016-02-24 National Research Council Of Canada Antagonisten von Liganden und ihre Verwendung
WO2009010539A2 (de) * 2007-07-19 2009-01-22 Ablynx. N.V. Receptor for interleukin-6 (il-6) form macaca fascicularis
US7960343B2 (en) 2007-09-18 2011-06-14 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion
CA2704038A1 (en) * 2007-10-31 2009-05-07 The Scripps Research Institute Combination therapy to treat persistent viral infections
US8004669B1 (en) 2007-12-18 2011-08-23 Plexera Llc SPR apparatus with a high performance fluid delivery system
NZ621443A (en) 2008-04-11 2015-09-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
DK3750552T3 (da) 2008-08-14 2023-07-24 Acceleron Pharma Inc Gdf-fælder
EP2326670A4 (de) * 2008-09-17 2014-04-16 Nat Res Council Canada Hetero-multivalente bindemittel für elemente der tgf-beta-superfamilie
EA201100832A1 (ru) 2008-11-26 2011-12-30 Амген Инк. Варианты полипептидов рецептора iib активина и их применение
JP5912078B2 (ja) 2009-06-08 2016-04-27 アクセルロン ファーマ， インコーポレイテッド 熱発生性脂肪細胞を増加させるための方法
JP2012529294A (ja) 2009-06-12 2012-11-22 アクセルロン ファーマ， インコーポレイテッド 切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JP2014502260A (ja) 2010-11-08 2014-01-30 アクセルロン ファーマ， インコーポレイテッド Ａｃｔｒｉｉａ結合剤およびその使用
CA2833147A1 (en) 2011-04-15 2012-10-18 Anita SESHIRE Anti- il-1r1 inhibitors for use in cancer
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
EA201491231A8 (ru) 2011-12-19 2015-01-30 Амген Инк. Варианты полипептидов рецептора активина и их применение
RU2678117C2 (ru) 2012-11-02 2019-01-23 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
CA2894219C (en) * 2012-12-10 2020-08-11 Vib Vzw Novel interleukin-33 inhibitors
EA201591423A1 (ru) 2013-02-01 2016-01-29 Санта Мария Биотерапевтикс, Инк. Введение антитела к активину-а пациентам
BR112015019729B1 (pt) 2013-02-15 2023-01-24 R-Pharm International, Llc Composições de proteína heterodimérica capaz de se ligar à il-1ss humana, composição terapêutica compreendendo-as, ácidos nucléicos, sistema de expressão heteróloga in vitro e uso de uma substância para o tratamento ou prevenção de uma doença associada com modulação da atividade da il-1ss humana
MA40008A (fr) 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
EP3170005B1 (de) 2014-07-18 2019-04-10 Sanofi Verfahren zur vorhersage des ausgangs einer behandlung mit aflibercept bei einem patienten mit verdacht auf ein krebsleiden
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41116A (fr) 2014-12-01 2017-10-10 Ferring Bv Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif
HUE054742T2 (hu) 2014-12-01 2021-09-28 Ferring Bv Szelektív IL-6-transz-szignalizációs inhibitor beadása
EP4233889A3 (de) 2014-12-03 2023-10-11 Celgene Corporation Activin-actrii-antagonisten und verwendungen davon zur behandlung von myelodysplastischem syndrom
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
JP7421338B2 (ja) 2016-09-27 2024-01-24 エピセントアールエックス，インコーポレイテッド 免疫調節融合タンパク質
MX2019012570A (es) * 2017-04-21 2019-12-02 Kindred Biosciences Inc Molecula del receptor de interleucina 4/interleucina 13 para uso veterinario.
CN111511769A (zh) 2017-09-27 2020-08-07 埃皮辛特瑞柯斯公司 免疫调节性融合蛋白
AR114275A1 (es) 2018-03-09 2020-08-12 Agenus Inc Anticuerpos anti-cd73 y métodos de uso de los mismos
WO2020018700A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
CN110950965B (zh) * 2018-09-26 2021-10-15 重庆精准生物技术有限公司 抗人cd123的嵌合抗原受体及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
AU651596B2 (en) * 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
ATE309376T1 (de) * 1990-06-28 2005-11-15 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
EP0533006A1 (de) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimäre Interleukin 5-Rezeptor/Immunoglobulin-Polypeptide
DE69230862T2 (de) * 1991-10-15 2000-12-14 Michael F Mullarkey Rezeptoren zur Behandlung von Entzündungen vom verzögerten Typ
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
DK0643719T3 (da) * 1992-03-09 1999-06-28 Ludwig Inst Cancer Res Nukleinsyresekvenser, som koder for eller er komplementære til nukleinsyresekvenser, som koder for interleukin 9-receptor
US8211422B2 (en) * 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
WO1993019163A1 (en) * 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
DE69333027T2 (de) * 1992-03-30 2004-05-06 Immunex Corp., Seattle Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
JP3255699B2 (ja) 1992-04-23 2002-02-12 味の素株式会社 ヒトＩＬ−２レセプターγ鎖分子
CA2160011A1 (en) * 1993-04-06 1994-10-13 Philip D. Greenberg Chimeric cytokine receptors in lymphocytes
EP0716703A1 (de) * 1993-09-03 1996-06-19 PRENDERGAST, Kenneth, Francis Glycophorin bindende proteine (gbp130) fusionszusammensetzungen
EP0726948B1 (de) * 1993-10-14 2007-02-28 President And Fellows Of Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
IL114825A0 (en) * 1994-08-04 1995-12-08 Regeneron Pharma Rtk/cytokine receptor chimeras
WO1996011213A1 (en) 1994-10-07 1996-04-18 Amgen Boulder Inc. Dimeric il-4 inhibitors
US5837544A (en) * 1995-02-02 1998-11-17 Cell Genesys, Inc. Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
US5837816A (en) * 1995-05-10 1998-11-17 Chiron Corporation Interleukin-2 receptor subunit ectodomain fusion protein comprising a leucine zipper domain
GB9526131D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US5776731A (en) * 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
AU3668897A (en) * 1996-07-17 1998-02-09 University Of Medicine And Dentistry Of New Jersey Chimeric receptors for jak-stat signal transduction
WO1998008969A1 (en) * 1996-08-26 1998-03-05 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
CA2318482C (en) * 1998-01-23 2010-04-13 Immunex Corporation Il-18 receptors

Also Published As

Publication number Publication date
ATE283365T1 (de) 2004-12-15
JP3902728B2 (ja) 2007-04-11
AU758970B2 (en) 2003-04-03
EP1115876A2 (de) 2001-07-18
ES2267300T3 (es) 2007-03-01
WO2000018932A2 (en) 2000-04-06
EP1229047A3 (de) 2002-10-02
EP1115876B1 (de) 2006-08-16
CN1357049A (zh) 2002-07-03
DE69922269D1 (de) 2004-12-30
JP2002525119A (ja) 2002-08-13
PL348529A1 (en) 2002-06-03
US6472179B2 (en) 2002-10-29
EP1405915A1 (de) 2004-04-07
DE69932832T2 (de) 2007-02-08
FR10C0025I2 (fr) 2011-04-01
CA2345109C (en) 2012-12-18
AU6499499A (en) 2000-04-17
NO329976B1 (no) 2011-01-31
AU758970C (en) 2007-05-03
CN100345970C (zh) 2007-10-31
NO2011003I1 (no) 2011-05-02
ES2233733T3 (es) 2005-06-16
NO2011003I2 (de) 2011-04-11
EP1229047A2 (de) 2002-08-07
HK1035377A1 (en) 2001-11-23
IL142103A0 (en) 2002-03-10
EP1229047B1 (de) 2004-11-24
HK1045847B (zh) 2005-03-24
NO20011513D0 (no) 2001-03-23
DE122010000023I1 (de) 2012-04-26
PT1229047E (pt) 2005-03-31
US20020164690A1 (en) 2002-11-07
CA2345109A1 (en) 2000-04-06
ATE336583T1 (de) 2006-09-15
PL201246B1 (pl) 2009-03-31
WO2000018932A9 (en) 2000-08-31
DE69922269T2 (de) 2005-12-01
US20020012962A1 (en) 2002-01-31
DE122010000023I2 (de) 2012-04-26
NO20011513L (no) 2001-05-25
FR10C0025I1 (de) 2010-05-21
HK1045847A1 (en) 2002-12-13
BE2010C021I2 (de) 2018-12-04
NZ510720A (en) 2003-11-28
DK1229047T3 (da) 2005-02-21
WO2000018932A3 (en) 2000-11-02
IL142103A (en) 2007-07-04

Similar Documents

Publication Publication Date Title
DE69932832D1 (de) Antagonisten auf rezeptorgrundlage und verfahren zur deren herstellung und verwendung
ATE420970T1 (de) Auf il-1-rezeptor beruhende antagonisten sowie herstellungs- und verwendungsverfahren
CY1112101T1 (el) Νευροτροφικοι παραγοντες
EA200401591A1 (ru) Керамические аноды и способ их изготовления
DE60223644D1 (de) Feststoffbrenner, Verfahren zur Verwendung desselben, Brennkessel und Verfahren für dessen Betrieb
ATE490323T1 (de) Adiponektin-rezeptor und dafür kodierendes gen
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DE60137223D1 (de) Thymus-stroma lymphopoietin rezeptor-moleküle und deren verwendung
DK1141286T3 (da) Kæde af cytokinreceptorer
DE69633563D1 (de) Neues verfahren zur gewinnung und reinigung von fusionsproteinen
ATE319814T1 (de) Luciferase, fluoreszenzproteine, für luciferase und fluoreszenzproteine kodierend nukleinsaüre und ihre verwendung in der diagnose, hoch- durchsatz screeningsverfahren
ATE279441T1 (de) Verfahren zur herstellung von genetisch veränderten lymphozyten vorläuferzellen von wirbeltieren und deren gebrauch zur produktion von heterologen bindeproteinen
DE69507017D1 (de) Cai-resistenzproteine kodierende dna, und ihre verwendung
DE60320302D1 (de) Verfahren zur identifikation von modulatoren des humanen orexin-2-rezeptors
ATE269905T1 (de) Verfahren zur herstellung von proteinen in wirtszellen unter verwendung von chaperoninen
DE69935973D1 (de) Zusammensetzungen mit fusionsproteinen der kinase wee1, nukleotidsequenzen, expressionsysteme und verfahren zu deren verwendung
DE50211528D1 (de) Verfahren zur herstellung einer normalisierten genbank aus nukleinsäure-exktrakten von bodenproben und deren verwendung
ATE393213T1 (de) Dendritische zelle mit alpha-glycosylceramid- derivat und antigen zur verwendung bei der unterdrückung von immunreaktionen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition